Community Health Systems, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYH research report →
Range $2.5 – $3.25
Price Chart
About the company
Community Health Systems, Inc. (CYH) operates as a major healthcare provider across the United States, focusing on the ownership, leasing, and management of general acute care hospitals. The organization offers a comprehensive array of medical services, including emergency care, general and specialized surgical procedures, critical care, internal medicine, obstetrics, and various diagnostic capabilities.
- CEO
- Kevin J. Hammons
- IPO
- 2000
- Employees
- 50,500
- HQ
- Franklin, TN, US
Get TickerSpark's AI analysis on CYH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $228.46M
- P/E
- 7.48
- PEG
- -0.08
- P/S
- 0.02
- P/B
- -0.18
- EV/EBITDA
- 6.12
- Div Yield
- 0.00%
- Gross Margin
- 69.98%
- Op Margin
- 10.86%
- Net Margin
- 0.31%
- ROE
- -2.51%
- ROIC
- 5.69%
Latest fiscal year · YoY change
- Revenue
- $12.48B-1.2%
- Gross Profit
- $1.49B-71.8%
- Op Income
- $1.49B
- Net Income
- $509.00M+198.6%
- EPS
- $3.81+197.7%
- OCF Growth
- +13.1%
- FCF Growth
- +73.3%
- 52W High
- $3.92
- 52W Low
- $1.52
- 50D MA
- $2.65
- 200D MA
- $2.96
- Beta
- 1.90
- RSI (14)
- 25
- Avg Volume
- 1.63M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Community Health Systems posted a softer-than-expected third quarter as uninsured volume and weaker commercial elective procedures pressured margins, but management said volume indicators, cost controls, and cash flow remain supportive of the full-year outlook.· October 29, 2026
- Adjusted EBITDA was $280 million in Q3, with margin of 10.2% versus 12.2% a year ago.
- Same-store net revenue rose 3.8% year over year, while same-store adjusted admissions grew 3.6% and same-store surgeries increased 2%.
- Management said a larger share of volume growth came from uninsured patients, while commercial elective procedures remained below expectations.
- Cost discipline remained strong: same-store operating expense per adjusted admission rose 2.1%, or 1.3% excluding provider taxes, and supply expense per adjusted admission declined.
- Full-year 2026 guidance was lowered to $11.3 billion-$11.5 billion of net revenue and $1.225 billion-$1.275 billion of adjusted EBITDA, with CFO raising the cash flow from operations outlook to $100 million-$300 million.
Third-quarter 2026 adjusted EBITDA was $280 million, with an adjusted EBITDA margin of 10.2% versus 12.2% in the prior-year period. Same-store net revenue growth was 3.8% year over year, same-store admissions increased 2.2%, same-store adjusted admissions increased 3.6%, and same-store surgeries increased 2%. Same-store net revenue per adjusted admission rose 0.2%, while same-store operating expense per adjusted admission increased 2.1% and 1.3% excluding provider taxes. Cash generated from operations for Q3 2026 was $168 million, adjusted to exclude taxes on divestiture gains, versus $121 million a year ago. Full-year 2026 guidance was updated to net revenue of $11.3 billion-$11.5 billion, adjusted EBITDA of $1.225 billion-$1.275 billion, and cash flow from operations of $100 million-$300 million. The company also said year-one Rural Health Transformation Program awards are expected to be $25 million-$30 million, and it expects to receive most grant funds in 2027, with income recognized over multiple periods starting in 2027.
Kevin Hammons said the quarter showed strong clinical execution and improving market share indicators, but patient behavior and affordability pressures are delaying higher-acuity elective procedures. He emphasized that clinic visits rose 7.9%, imaging was strong, physician turnover improved, and the company is seeing deferred rather than lost demand. His tone was confident but cautious, with a clear focus on quality, physician retention, outpatient expansion, and proactive cost reduction.
Jason Johnson said results came in below internal expectations because of unfavorable payer and service mix, including higher uninsured volume and weaker commercial elective demand. He cited adjusted EBITDA of $280 million, margin of 10.2%, cash from operations of $168 million in Q3, and reiterated that same-store operating expense per adjusted admission rose 2.1% but only 1.3% excluding provider taxes. He also noted net leverage of 7.2x at quarter end, no ABL borrowings, the next significant debt maturity in 2029, and unchanged capex guidance of $350 million-$400 million. He quantified HIX-related pressure at $80 million-$90 million for full-year 2026, said year-one Rural Health funds should be $25 million-$30 million, and pointed to $15 million-$20 million of 2026 state-directed payment benefits that will not repeat in 2027.
Analysts pressed on whether weaker orthopedic and elective surgery volumes reflect permanent share loss or simply deferral from higher deductibles and macro pressure. Management said the demand is mostly being deferred, not lost, with commercial patients delaying procedures while clinic visits and imaging remain strong, and said much of the growth in uninsured volume is showing up in ER utilization. Questions also focused on 2027 economics, where management flagged both tailwinds such as rate updates, deferred procedure recovery, and outpatient/ASC growth, and headwinds including potential Medicaid work-requirement impacts, uninsured pressure, and continued medical specialty cost inflation. On cash flow and capital spending, management said it remains comfortable with the updated guidance and has not reduced capex plans.
The company sees multiple signs that demand is still in its network: clinic visits rose 7.9%, imaging grew, same-store adjusted admissions rose 3.6%, and surgeries turned positive at 2% after several down quarters. Management believes elective procedures are being delayed rather than lost, which could support a rebound if affordability improves or patients reset deductibles. Cost savings initiatives, physician retention gains, outpatient expansion, and Rural Health-related opportunities could all help offset current pressure.
The quarter exposed a meaningful earnings reset from higher uninsured volume, weaker commercial elective procedures, and an unfavorable payer mix. Management also highlighted that self-pay collections are slowing, medical specialties costs remain well above expectations, and HIX/coverage-related pressure is likely to continue near term. Looking ahead, 2027 still has several uncertainties, including Medicaid work requirements, provider tax changes, and whether deferred elective demand actually returns in a timely way.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 77.9%
- Shares Outstanding
- 141.03M
- Float Shares
- 109.89M
of shares held by institutions
188 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Castleknight Management LP | 13.38M | ▲ 717.00K |
| Apollo Management Holdings, L.P. | 11.86M | ▲ 370.21K |
| Blackrock, Inc. | 10.54M | ▼ 395.37K |
| Vanguard Group Inc | 9.17M | ▲ 614.77K |
| Eversept Partners, LP | 7.86M | ▼ 812.71K |
| Nomura Holdings Inc | 6.70M | ▼ 181.90K |
| Vanguard Capital Management LLC | 5.13M | ▼ 164.25K |
| Whitebox Advisors LLC | 3.73M | ▲ 604.86K |
| State Street Corp | 3.16M | ▲ 97.61K |
| Vanguard Portfolio Management LLC | 2.99M | ▼ 31.66K |
| Saba Capital Management, L.P. | 2.88M | ▲ 1.60M |
| Geode Capital Management, LLC | 2.77M | ▼ 398.19K |
Held by 174 ETFs
Biggest fund positions in CYH by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 25, 26 | JENNINGS WILLIAM NORRIS | sell | 40,000 |
| Jun 30, 26 | Krishnan K Ranga | other | 13,930 |
| Jun 30, 26 | Krishnan K Ranga | other | 13,930.678 |
| Jun 1, 26 | Rice David V. | other | 30,000 |
| Jun 1, 26 | Rice David V. | other | 30,000 |
| Jun 1, 26 | Rice David V. | other | 30,000 |
| May 12, 26 | Rice David V. | other | 0 |
| Apr 22, 26 | Krishnan K Ranga | other | 46,950 |
| Apr 22, 26 | Krishnan K Ranga | other | 46,950 |
| Mar 1, 26 | STOCKTON KEVIN A | other | 30,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CYH coverage
Recent articles, reports, and earnings notes.
No research on CYH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CYH report →Community Health Systems Sees Surgery Delays Stretching Into Next Year as Costs Squeeze Patients
marketbeat.com · Nov 12
Community Health Systems, Inc. (CYH) Presents at 2026 UBS Global Healthcare Conference Transcript
seekingalpha.com · Nov 10
Community Health Systems Announces Proposed Exchange Offer and Consent Solicitation
businesswire.com · Nov 9
Community Health Systems: Long-Term Optimism About Their Turnaround Potential
seekingalpha.com · Nov 6
Community Health Systems Announces Participation in the 2026 UBS Global Healthcare Conference
businesswire.com · Nov 3
What Community Health Systems (CYH) Said on Its Q3 Earnings Call
marketbeat.com · Oct 30
Community Health Systems, Inc. (CYH) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 29
Here's What Key Metrics Tell Us About Community Health Systems (CYH) Q3 Earnings
zacks.com · Oct 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.